此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

手术前抗生素(头孢唑啉)对 I-II 期黑色素瘤患者微生物组的影响

2026年11月6日 更新者:M.D. Anderson Cancer Center

评估围手术期抗生素预防对皮肤恶性肿瘤患者微生物组的影响

This phase I trial investigates the impact of cefazolin before surgery on the microbiome in patients with stage I-II melanoma. Antibiotics, such as cefazolin, given at the time of surgery may cause a significant change in the microbes (like bacteria and viruses) found in the stomach and intestines. This trial may help researchers learn if any changes in microbes affect the body's ability to respond to surgery and cancer.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To investigate whether the use of pre-operative prophylactic antibiotics administered during surgical resection substantially alters the patient's gut microbiome.

SECONDARY OBJECTIVES:

I. To characterize the dynamics of the immune response to surgical intervention in the absence and presence of pre-operative prophylactic antibiotics, focusing on the immune profile of the peripheral blood leukocytes as well as the balance of circulating pro- and anti-inflammatory cytokines and metabolomic profiles.

II. To assess surgical site infection (SSI) in the absence and presence of pre-operative prophylactic antibiotics at time of surgical resection.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive cefazolin intravenously (IV) and then undergo standard of care surgical resection within 1 hour.

ARM B: Patients undergo standard of care surgical resection.

After completion of study treatment, patients are followed up at 3 days, 2 weeks, and 3 months.

研究类型

介入性

注册 (估计的)

20

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • M D Anderson Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult subjects with early stage melanoma (stage I-II)
  • Patients must be undergoing wide local excision +/- sentinel lymph node biopsy
  • Patients must be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion Criteria:

  • Use of antibiotics within the three months prior to surgery
  • Allergy, sensitivity or anaphylaxis to beta-lactam or cephalosporin antibiotics
  • Presence of an infection at the time of surgery
  • Increased risk of infection due to a co-existing medical condition as determined by the surgical team or principal investigator (PI)
  • Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration
  • American Society of Anesthesiologists (ASA) grade > IV
  • Refusal to participate in the study
  • Patients who are pregnant will not be included in this study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Arm A (cefazolin, surgical resection)

Patients receive cefazolin IV and then undergo standard of care surgical resection within 1 hour.

Given IV

Undergo standard of care surgical resection

其他名称:
  • 手术切除
实验性的:Arm B (surgical resection)

Patients undergo standard of care surgical resection.

Undergo standard of care surgical resection

其他名称:
  • 手术切除

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in microbiome alpha diversity
大体时间:Baseline up to 2 weeks post-surgery

The diversity, structure, and composition of the fecal microbiome will be determined by 16S(v4) rRNA gene sequencing. 16S profiles will be used to compute alpha diversity, beta diversity, and the relative abundance of fecal bacteria. The composition of fecal bacteria in adult humans is mainly dominated by members of the Firmicutes and Proteobacteria phyla while members of Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia are observed in lower abundance. To calculate richness (alpha-diversity), we will count each operational taxonomic unit (OTU) or amplicon sequence variant (ASV) identified. Richness count is expected to range between 10-500 per sample.

Baseline up to 2 weeks post-surgery

次要结果测量

结果测量
措施说明
大体时间
微生物相对丰度的变化
大体时间:基线,术后 2 周和术后 3 个月
基线,术后 2 周和术后 3 个月
伤口(手术部位)感染率
大体时间:手术后长达 3 个月
手术后长达 3 个月
Change in microbiome diversity
大体时间:Baseline up to 3 months post-surgery

The diversity, structure, and composition of the fecal microbiome will be determined by 16S(v4) rRNA gene sequencing. 16S profiles will be used to compute alpha diversity, beta diversity, and the relative abundance of fecal bacteria. The composition of fecal bacteria in adult humans is mainly dominated by members of the Firmicutes and Proteobacteria phyla while members of Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia are observed in lower abundance. To calculate richness (alpha-diversity), we will count each operational taxonomic unit (OTU) or amplicon sequence variant (ASV) identified. Richness count is expected to range between 10-500 per sample.

Baseline up to 3 months post-surgery
Profiling of systemic immune function by analysis of composition of circulating immune cell populations and cytokines
大体时间:Up to 3 months post-surgery

By analysis of composition of circulating immune cell populations and cytokines.

Up to 3 months post-surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Emily Z Keung、M.D. Anderson Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年9月8日

初级完成 (估计的)

2027年2月2日

研究完成 (估计的)

2027年2月2日

研究注册日期

首次提交

2020年10月5日

首先提交符合 QC 标准的

2021年5月3日

首次发布 (实际的)

2021年5月6日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2020-0265
  • 2020-0265 (其他标识符:M D Anderson Cancer Center)
  • NCI-2020-07071 (注册表标识符:CTRP (Clinical Trial Reporting Program))

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅